30 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
10 May 24
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
4:07pm
to $45 million, consistent with previous guidance and driven primarily by expenses for our program in Alzheimer’s disease.
Research and development (R&D) expenses … were $16.2 million. This compared to $22.1 million for the same period in 2023. R&D expenses decreased due primarily to the completion
8-K
EX-99.1
SAVA
Cassava Sciences Inc
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
in Alzheimer’s disease.
Research and development (R&D) expenses were $89.4 million. This compared to $68 million for 2022. R&D expenses increased due
8-K
EX-99.1
SAVA
Cassava Sciences Inc
7 Nov 23
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
9:08am
guidance and driven primarily by expenses for our clinical program in Alzheimer’s disease.
Research and development (R&D) expenses were $23.6 million … . This compared to $18.5 million for the same period in 2022. R&D expenses increased due primarily to increasing patient enrollment and costs to conduct
8-K
EX-99.1
SAVA
Cassava Sciences Inc
3 Aug 23
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
9:12am
is expected to be $40 to $50 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.
Research and development (R&D) expenses … were $25.0 million. This compared to $16.9 million for the same period in 2022. R&D expenses increased due primarily to increasing patient
8-K
EX-99.1
bpgu8mze5h1 4p
1 May 23
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
9:05am
8-K
EX-99.1
ucfe8xvlk1aphrmjm1r
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am
8-K
EX-99.1
lm16ki1n7ff 950t3zu
3 Aug 22
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
9:25am
8-K
EX-99.1
xd9 wnqg6wl46m251
5 May 22
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
9:04am
8-K
EX-99.1
76s132
28 Feb 22
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
12:00am
8-K
EX-99.1
zht4bj t09
10 Nov 21
Cassava Sciences Reports Third Quarter 2021 Financial Results
9:10am
8-K
EX-99.1
sq6m39ha5bc9nj
3 Aug 21
Cassava Sciences Reports Second Quarter 2021 Financial Results
8:45am
8-K
EX-99.1
qdv1qjv6ujav3ca9abq
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-99.1
no6q6jeerns00
9 Nov 20
Cassava Sciences Reports Third Quarter 2020 Financial Results
8:30am
8-K
EX-99.1
su9 x7ltq
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.1
nyzr8emo2i
6 May 20
Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
8:16am
8-K
EX-99.1
v1q9wdyye9d aka
29 Oct 19
Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results
8:29am